<DOC>
	<DOCNO>NCT02455024</DOCNO>
	<brief_summary>This observational study characterize safety profile patient chronic myeloid leukemia chronic phase ( CP-CML ) treat Iclusig ( ponatinib ) routine clinical practice US . The study focus analysis vascular occlusive event .</brief_summary>
	<brief_title>An Observational Study Evaluate Incidence Risk Factors Vascular Occlusive Events Associated With Iclusig®</brief_title>
	<detailed_description>The study conduct effort well understand rate , risk factor , outcomes associate vascular occlusive event patient treat Iclusig ( ponatinib ) real world setting . This study collect information patient demographic , leukemia diagnosis , previous anti-cancer treatment , history cardiovascular disease , risk factor vascular complication , concurrent medication ( include antiplatelet and/or anticoagulant agent ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<criteria>1 . Adult patient CPCML ( age ≥ 18 year ) initiate Iclusig monotherapy , Iclusig monotherapy initiate within 2 week study enrollment . [ The decision prescribe Iclusig must make prior enrollment study ] . 2 . Patients ability understand requirement study provide write informed consent comply study data collection procedure . 3 . Patients minimum life expectancy 3 month . 1 . Patients previously treat investigational ponatinib ( Iclusig ) . 2 . Patients receive investigational agent ( e.g. , drug biologic agent medical device receive approval US ) . 3 . Concurrent treatment another TKI CML . 4 . Prior history AP BPCML . 5 . Patients pregnant and/or breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Leukemia , Myeloid</keyword>
	<keyword>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</keyword>
	<keyword>ponatinib</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Protein Kinase Inhibitors</keyword>
	<keyword>Risk factor</keyword>
	<keyword>Leukemia , Myelogenous , Chronic</keyword>
	<keyword>CML</keyword>
	<keyword>CP-CML</keyword>
	<keyword>Iclusig</keyword>
	<keyword>AP24534</keyword>
</DOC>